Clinical Trial Update: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the addition of the AKT inhibitor ipatasertib to standard chemotherapy and radiation for locally advanced head and neck s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Nasal Cavity Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma

Drugs mentioned

• ipatasertib (ipatasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary | Phase 1 | Status: RECRUITING